Cardium's Generx Advances To Phase 3 Following Meeting With FDA (Exercise treadmill)

Cardium's Generx Advances To Phase 3 Following Meeting With FDA
Cardium Therapeutics, Inc (OTC Bulletin Board: CDTP) announced that Generx(TM) (alferminogene tadenovec) is to be advanced to a Phase 3 clinical trial in women as a potential treatment for myocardial ischemia (insufficient blood flow within the heart muscle), following an end-of-Phase 2 meeting with the U.S. Food and Drug Administration (FDA). [click link for full article]
Source: www.medicalnewstoday.com